ReviewPituitary2004
The role of somatostatin analogs in Cushing's disease.
Review in Pituitary, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 50 citations in OpenAlex.
- Anti-secretory and anti-proliferative actions of next-generation dual subtype 2 and 5 somatostatin receptor ligands in neuroendocrine tumor models.Frontiers in oncology · 2026Article
- miR-375 Regulation of SSTR2 Expression in Corticotroph Pituitary Cells: Somatostatin Receptor Ligands Effects.Endocrinology · 2025Article
- Cushing's Disease Manifestation inInternational journal of molecular sciences · 2024Article
- New Trends in Treating Cushing's Disease.TouchREVIEWS in endocrinology · 2024Article
- The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas.International journal of molecular sciences · 2022Review
- Pasireotide treatment in Cushing's disease: A single tertiary center's experience.Turkish journal of medical sciences · 2022Article
- Somatostatin Analogs in Clinical Practice: a Review.International journal of molecular sciences · 2020Review
- A review of Cushing's disease treatment by the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism.Archives of endocrinology and metabolism · 2018Review
- Pituitary-Directed Therapies for Cushing's Disease.Frontiers in endocrinology · 2018Review
- Article
- Molecular basis of pharmacological therapy in Cushing's disease.Endocrine · 2014Review
- Medical management of functioning pituitary adenoma: an update.Neurologia medico-chirurgica · 2014Review
- Chemometric evaluation of urinary steroid hormone levels as potential biomarkers of neuroendocrine tumors.Molecules (Basel, Switzerland) · 2013Article
- Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.Pituitary · 2011Article
- Structural determinants of agonist-selective signaling at the sst(2A) somatostatin receptor.Molecular endocrinology (Baltimore, Md.) · 2011Article
- Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.Molecular endocrinology (Baltimore, Md.) · 2010Article
- Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.Reviews in endocrine & metabolic disorders · 2009Review
- Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.Biologics : targets & therapy · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Somatostatin (SRIF) has been proposed to be of therapeutic interest in the medical treatment of Cushing's disease. While in vitro data demonstrate the presence of SRIF-receptor subtype (sst) expression in corticotroph adenomas, the current clinically available SRIF-analog Octreotide, predominantly targeting sst(2), is ineffective in lowering ACTH levels in Cushing's disease and only appears to inhibit the release of ACTH in Nelson's syndrome. In the present review, current knowledge on the physiological role of SRIF in the regulation of ACTH secretion by the anterior pituitary gland, as well as by corticotroph tumor cells is summarized. In addition, the role of glucocorticoids in regulating sst-mediated inhibition of ACTH release by corticotroph adenoma cells is discussed. Recently, it was reported that the novel multiligand SRIF-analog SOM230 might have the potential to be of therapeutic interest for Cushing's disease. On the basis of the potent suppressive effects on ACTH release by SRIF-analogs with high binding affinity to sst(5) and the observation that sst(5) expression and action is relatively resistant to glucocorticoid treatment, including the recent observation that sst(5) is the predominant sst expressed in human corticotroph adenomas, it is hypothesized that sst(5) may be a new therapeutic target for the control of ACTH and cortisol hypersecretion in patients with pituitary dependent Cushing's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.